The Delhi High Court has permitted Dr Reddy’s Laboratories to produce and export its version of the diabetes and anti-obesity drug semaglutide. This decision comes amidst a patent infringement case filed by Novo Nordisk. Dr Reddy’s is restricted from selling the drug within India until March 2026. The court acknowledged a valid challenge to Novo Nordisk’s patent for semaglutide.
